Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has received a commitment of US$40 million for its fifth biosciences fund, LAV Biosciences Fund V, from U.S. public pension San Francisco City & County Employees’ Retirement System (SFERS).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!Subscribe for $359
Already have an account or paid subscription?